Skip to content

Seikagaku Corp Sustainability Reports

Seikagaku Corporation focuses on the research, development, manufacture, and sale of pharmaceutical products and medical devices primarily related to glycoscience and glycoconjugates such as hyaluronic acid. The company operates through two main business segments comprising pharmaceutical products and limulus amebocyte lysate (LAL) reagents.

Sector: Manufacturing

Country: Japan

Exchange: Tokyo Stock Exchange

FIGI: BBG001S6J397

9 reports from 2019 to 2025